Free tool
FAERS Monitor: Timoptic
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018086 or its brand name (Timoptic, Timolol Maleate). Reports on generic versions are filed under their own applications.
Reports
9,481
Serious
4,819
51% of reports
Hospitalization
2,117
Death reported
575
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure1,009
- drug ineffective668
- eye pain503
- fatigue502
- eye irritation432
- dizziness363
- diarrhoea341
- nausea337
- vision blurred316
- dyspnoea309
- headache302
- off label use298
- intraocular pressure increased290
- death280
- fall278
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 250 |
| 2005 | 287 |
| 2006 | 250 |
| 2007 | 239 |
| 2008 | 218 |
| 2009 | 213 |
| 2010 | 290 |
| 2011 | 278 |
| 2012 | 385 |
| 2013 | 166 |
| 2014 | 205 |
| 2015 | 337 |
| 2016 | 384 |
| 2017 | 423 |
| 2018 | 435 |
| 2019 | 505 |
| 2020 | 1,537 |
| 2021 | 474 |
| 2022 | 500 |
| 2023 | 568 |
| 2024 | 560 |
| 2025 | 600 |
| 2026 | 376 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,678 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intraocular pressure increasedSignal | 290 | 51.5 | 45.9 | 13,990 |
| treatment failureSignal | 1,009 | 27.3 | 25.8 | 25,367 |
| eye painSignal | 503 | 19.9 | 18.3 | 8,977 |
| eye irritationSignal | 432 | 16.8 | 15.3 | 6,360 |
| vision blurredSignal | 316 | 5.1 | 4.6 | 1,046 |
| fall | 278 | 1.9 | 1.7 | 110 |
| dizziness | 363 | 1.6 | 1.5 | 86 |
| fatigue | 502 | 1.4 | 1.3 | 67 |
| dyspnoea | 309 | 1.2 | 1.1 | 11 |
| diarrhoea | 341 | 1.2 | 1.1 | 9 |
| drug ineffective | 668 | 1.1 | 1.0 | 10 |
| headache | 302 | 1.1 | 1.0 | 1 |
| nausea | 337 | 0.9 | 0.9 | 1 |
| off label use | 298 | 0.8 | 0.7 | 24 |
| death | 280 | 0.7 | 0.6 | 31 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.